Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Breast Cancer Res Treat. 2021 Apr;186(2):403-415. doi: 10.1007/s10549-021-06099-6. Epub 2021 Feb 2.
A uniform classification framework for neuroendocrine neoplasms (NENs) in all the organ systems has been recently proposed by an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert panel. Based on the new classification system, the NENs of the breast are divided into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). This study is aimed to analysis the prognostic differences between NENs and invasive ductal carcinomas of no special type (IDCs-NST).
The surveillance, epidemiology, and end results (SEER) database released on November 2018 was used for this study. Between 2003 and 2016, 361 NENs (NET = 239, NEC = 122) of the breast and 491,908 of IDCs-NST were identified. Survival analysis was performed for disease-specific survival (DSS) and overall survival (OS).
The 5-year DSS of NET, NEC, and IDC-NST was 63.39%, 46.00%, and 89.17%, respectively. And the 5-year OS of NET, NEC, and IDC-NST was 55.66%, 38.87%, and 83.17%, respectively. Within the same clinical stage or grade, NETs and NECs of the breast had worse DSS and OS than corresponding stage or grade IDCs-NST (all P < 0.050). In univariate and multivariate survival analysis, NENs of the breast had significantly worse DSS and OS than IDCs-NST (P < 0.001).
The universal classification framework for NEN allowed us to further refine the breast carcinoma with neuroendocrine differentiation as a unique pathologic and clinical entity, which has worse clinical outcome compared to IDC-NST.
国际癌症研究机构(IARC)和世界卫生组织(WHO)专家小组最近提出了一种用于所有器官系统神经内分泌肿瘤(NEN)的统一分类框架。根据新的分类系统,乳腺的 NEN 分为分化良好的神经内分泌肿瘤(NET)和分化差的神经内分泌癌(NEC)。本研究旨在分析 NEN 与非特殊型浸润性导管癌(IDC-NST)之间的预后差异。
本研究使用了 2018 年 11 月发布的监测、流行病学和最终结果(SEER)数据库。在 2003 年至 2016 年期间,共确定了 361 例乳腺 NEN(NET=239,NEC=122)和 491908 例 IDC-NST。对疾病特异性生存率(DSS)和总生存率(OS)进行生存分析。
NET、NEC 和 IDC-NST 的 5 年 DSS 分别为 63.39%、46.00%和 89.17%,5 年 OS 分别为 55.66%、38.87%和 83.17%。在相同的临床分期或分级中,乳腺的 NET 和 NEC 的 DSS 和 OS 均差于相应分期或分级的 IDC-NST(均 P<0.050)。在单因素和多因素生存分析中,乳腺 NEN 的 DSS 和 OS 明显差于 IDC-NST(P<0.001)。
用于 NEN 的通用分类框架使我们能够进一步将具有神经内分泌分化的乳腺癌作为一种独特的病理和临床实体进行细化,其临床结局较 IDC-NST 更差。